# PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

> **NCT00332202** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 758 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00332202
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-07
- **Target enrollment:** 758 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332202, "PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00332202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*